Article
The AI Industry Wants to Turn the Routine Mammogram into a Powerful Multitool
New tech wants to graduate from detecting existing cancers to predicting future risk.
Clairity’s approach is grounded in decades of work focused on the early identification of cancer. Review recent examples of research and news regarding Clairity and Clairity founder Dr. Connie Lehman, MD, PhD, related to computer aided diagnosis, deep learning, artificial intelligence, density assessment, predictive risk models, effective imaging workflow and risk-based triage.
New tech wants to graduate from detecting existing cancers to predicting future risk.
Clairity, developer of the first image-only AI model authorized by the U.S. Food and Drug Administration (FDA) that estimates a woman’s five-year risk of developing breast cancer from a routine mammogram, today announced the formation of a Strategic Advisory Board to support its product path and the broad rollout and adoption of Clairity’s predictive AI technologies at scale.
Clairity, Inc., an AI-driven precision health company pioneering image-based risk prediction, today announced the closing of a $43 million Series B financing.
During the broadcast, Dr. Connie Lehman shared a five-year breast cancer risk estimate for NBC anchor Savannah Sellers, generated from her mammogram images by the CLAIRITY BREAST AI platform.
For the first time, they will receive risk scores revealing their likelihood of developing the disease in the next five years, not based on their genetics or family history, but through features on their mammogram, visible only to an AI tool called Clairity Breast.
Routine mammograms are the mainstay of breast cancer screening. But, with a new type of analysis powered by artificial intelligence, doctors may be able to also predict whether or not you’ll develop breast cancer in the next few years.
About one in eight women will be diagnosed with the disease in their lifetimes. To combat that, some doctors are using AI as a tool to help them not only detect breast cancer, but also predict a woman’s risk factors.
Clairity, Inc., a company pioneering AI-powered risk prediction in human health, today announced that Founder Dr. Connie Lehman has been named to the Forbes “50 Over 50: Innovation” list.
Clairity Inc., a leader in AI-based breast cancer risk prediction, today announced that five scientific presentations featuring its FDA-authorized image-only AI model will be presented at the Radiological Society of North America (RSNA) 2025 Annual Meeting, taking place November 30 to December 4 in Chicago.
Health-tech companies are designing models that identify patients at risk of developing cancer, and who might need more screening or preventive care.
Clairity Breast is an AI-powered tool that is able to predict your risk for the disease in the next five years. Constance Lehman, M.D., Ph.D., the founder of Clairity Inc. and a Breast Cancer Research Foundation (BCRF) investigator, says that it employs deep learning, a form of AI that teaches computers to process data like the human brain.
A seismic shift is happening in how we understand and manage breast cancer risk. For decades, mammography was used primarily to detect cancer after it had already formed. But today, artificial intelligence (AI) and advanced imaging tools are enabling something once thought impossible: predicting cancer risk before it develops.
Breast cancer kills 42,000+ women in the USA annually. Connie Lehman, MD, PhD & Jeff Luber, JD, MBA of CLAIRITY, Inc. have received FDA authorization for the first A.I.-powered mammography tool – CLAIRITY BREAST – that predicts 5-year cancer risk. It will save many lives. For details go to Clairity.com
What if you could know your risk of developing breast cancer over the next five years? A Boston company is trying to do that using artificial intelligence.
BOSTON–(BUSINESS WIRE)–Clairity, Inc., advancing AI-powered human health solutions, today announced that members of its executive leadership team will be attending and participating in the upcoming BIO International Convention 2025, taking place June 16-19, 2025 in Boston, with its CEO, Jeff Luber, presenting the company update.
Clairity, Inc., a digital health innovator advancing AI-driven healthcare solutions, has received U.S. Food and Drug Administration (FDA) De Novo authorization for CLAIRITY BREAST, a novel, image-based prognostic platform designed to predict five-year breast cancer risk from a routine screening mammogram.
Clairity, Inc. is proud to announce a $1M investment from the Breast Cancer Research Foundation (BCRF) in support of Clairity, a leading innovator in AI-powered tools for breast cancer risk assessment.
Clairity, Inc., a pioneer in AI-based predictive tools for breast cancer, is pleased to announce the appointment of Jeffrey R. Luber, JD, MBA, as President, Chief Executive Officer and Director. Luber, an award-winning healthcare leader with extensive experience across oncology, genetic sequencing, infectious disease testing and digital health, will guide Clairity through market launch and global expansion.
Deep learning breast cancer risk models demonstrate improved accuracy compared to traditional risk models. This research highlights the promise deep learning models to support equitable, risk-based mammography screening.
Accurate density assessments could help health care systems more appropriately use limited supplemental screening resources and help better inform traditional clinical risk models.
The COVID-19 pandemic took a toll on mammography screening volumes among women of color, slashing exam uptake by more than 50% between 2019 and 2020.